# US 2019/0153428 A1 · Method for reducing immunogenicity of rna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153428 A1
- Document ID: US20190153428A1
- Status: Published application
- Kind: A1
- Application number: 15/755,309
- Filed: 2016-08-24
- Published: 2019-05-23
- Earliest claimed: 2015-08-28
- Assignees: BioNTech RNA Pharmaceuticals GmbH
- Applicants: BioNTech RNA Pharmaceuticals GmbH
- Inventors: Katalin KARIKO; Ugur SAHIN
- Web page: https://patentgrep.com/patent/US20190153428A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C07K 14/505: Erythropoietin [EPO]
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/67: General methods for enhancing the expression
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.

## Claims

### Claim 1

A method of decreasing immunogenicity of RNA, said method comprising modifying the nucleotide sequence of the RNA by reducing uridine (U) content thereof, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA.

### Claim 2 (depends on 1)

The method of claim 1 comprising the steps of:
(i) providing the nucleotide sequence of a first RNA,
(ii) designing the nucleotide sequence of a second RNA, said nucleotide sequence of the second RNA comprising a reduced U content compared to the nucleotide sequence of the first RNA, and, optionally,
(iii) providing the second RNA.

### Claim 3

A method of providing a nucleic acid molecule for RNA transcription comprising the steps of:
(i) providing a first DNA sequence encoding the nucleotide sequence of a first RNA,
(ii) designing a second DNA sequence encoding the nucleotide sequence of a second RNA, said nucleotide sequence of the second RNA comprising a reduced U content compared to the nucleotide sequence of the first RNA, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA, and
(iii) providing a nucleic acid molecule comprising the second DNA sequence.

### Claim 4 (depends on 1)

The method of claim 1, wherein the RNA encodes at least one peptide or protein.

### Claim 5 (depends on 4)

The method of claim 4, wherein the peptide or protein is pharmaceutically active or antigenic.

### Claim 6 (depends on 4)

The method of claim 4, wherein the amino acid sequence of the peptide or protein encoded by the RNA modified by reducing the U content is identical to the amino acid sequence of the peptide or protein encoded by the non-modified RNA.

### Claim 7 (depends on 1)

The method of claim 1, wherein said reduced U content renders the RNA modified by reducing the U content less immunogenic compared to the non-modified RNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the U content in the RNA modified by reducing the U content is reduced by at least 10%, preferably at least 20%, more preferably at least 30% compared to the non-modified RNA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the U content is reduced in one or more of the 5′ untranslated region, the coding region and the 3′ untranslated region of the RNA.

### Claim 10 (depends on 1)

The method of claim 1, wherein the U content is reduced in the coding region of the RNA.

### Claim 11 (depends on 1)

The method of claim 1, wherein said reduction of the U content comprises a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA.

### Claim 12 (depends on 1)

The method of claim 1, wherein said nucleosides other than U are selected from the group consisting of adenosine (A), guanosine (G), 5-methyluridine (m5U) and cytidine (C).

### Claim 13 (depends on 1)

The method of claim 1, wherein said reduction of the U content comprises a substitution of U nucleosides by adenosine (A) nucleosides.

### Claim 14 (depends on 1)

The method of claim 1, wherein said reduction of the U content comprises altering codons which comprise at least one U nucleoside by other codons that encode the same amino acids but comprise fewer U nucleosides and preferably comprise no U nucleosides.

### Claim 15 (depends on 1)

The method of claim 1, further comprising introducing at least one analogue of a naturally occurring nucleoside into the nucleotide sequence of the RNA.

### Claim 16 (depends on 15)

The method of claim 15, wherein introducing the analogue of a naturally occurring nucleoside into the nucleotide sequence of the RNA reduces immunogenicity of the RNA.

### Claim 17 (depends on 15)

The method of claim 15, wherein introducing at least one analogue of a naturally occurring nucleoside into the nucleotide sequence of the RNA comprises a substitution of U nucleosides by pseudouridines.

### Claim 18 (depends on 1)

The method of claim 1, wherein the RNA is mRNA.

### Claim 19 (depends on 3)

A method of obtaining RNA comprising the steps of (i) providing a nucleic acid molecule for RNA transcription according to the method of claim 3, and (ii) transcribing RNA using the nucleic acid molecule as a template.

### Claim at position 20

20-23. (canceled)
